Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09WCN
|
|||
| Former ID |
DNCL002549
|
|||
| Drug Name |
Intetumumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | |
| Company |
Janssen Biotech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.